A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

Trial Profile

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
  • Indications Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 06 Jun 2017 Results (n=23) assessing efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial carcinoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 Results from a combined analysis of endometrial carcinoma patients over both the Phase Ib and Phase II parts of the study (n=23) published in an Eisai Co Ltd media release.
    • 03 Jun 2017 Interim results of first evaluable cohort (metastatic endometrial cancer, n = 23) presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) according to an Eisai media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top